Prospective Observational Study Evaluating the Safety of Lenalidomide/Dexamethasone Treatment in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase IV
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms PrObe-L
- Sponsors Celgene Corporation
- 06 Mar 2018 Planned End Date changed from 1 Sep 2023 to 29 Sep 2023.
- 06 Mar 2018 Planned primary completion date changed from 1 Sep 2023 to 29 Sep 2023.
- 02 Mar 2016 New trial record